<b>Conclusions:</b> This case suggested that breast cancer coexisting with HER-2 amplification and EGFR E19 del may be driven by both HER-2 and EGFR signaling pathways, and patients can benefit from EGFR-TKI and anti-HER-2 therapy. This evidence concerns the gene ERBB2 and breast carcinoma.